Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

61. Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial

Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard (...) collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions , 37 (33), 3111-3123 2019 Nov 20 Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial

2020 EvidenceUpdates

62. British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines Full Text available with Trip Pro

British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England Post-Polypectomy and Post-Colorectal Cancer Resection Surveillance Guidelines - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) Post-Polypectomy and Post-Colorectal Cancer Resection Surveillance Guidelines , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Gastroenterology, University Hospital of North Tees, Stockton-on-Tees, UK matt.rutter@nth.nhs.uk. 2 Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK. 3 Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK. 4 Gastroenterology, South Tyneside NHS Foundation Trust, South Shields, UK. 5 Western

2020 EvidenceUpdates

63. Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced (...) characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions , 37 (34), 3266-3274 2019 Dec 1 Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Thomas Jefferson

2020 EvidenceUpdates

64. Which population groups are more likely to delay presentation with cancer symptoms and are more frequently diagnosed with late stage cancer, and why?

Which population groups are more likely to delay presentation with cancer symptoms and are more frequently diagnosed with late stage cancer, and why? Knowledge & Library Services (KLS) Evidence Briefing Which population groups are more likely to delay presentation with cancer symptoms and are more frequently diagnosed with late stage cancer, and why? Anh Tran 29 th March 2019 Which population groups are more likely to delay presentation with cancer symptoms and are more frequently diagnosed (...) with late stage cancer, and why? KLS Evidence Briefing 29 th March 2019 Question This briefing summarises the evidence on delayed cancer presentation and late stage cancer diagnosis from January 2008 - January 2019 Key messages • Amongst all the population groups considered, the main reason for delay in presenting with cancer symptoms is lack of knowledge and not recognising cancer symptoms. • Opportunities for diagnosing cancer in younger people are frequently missed in primary care. This may in part

2020 Public Health England - Evidence Briefings

65. Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer

Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer Overview | Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer | Guidance | NICE Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer Technology appraisal guidance [TA620] Published date: 15 January 2020 Share Save Guidance on olaparib (Lynparza) for maintenance (...) treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults with a BRCA1 or BRCA2 mutation. Is this guidance up to date? Next review : Recommendation 1.1 will be considered for review in 2023. Recommendation 1.2 will be updated after June 2020 when more evidence on olaparib has been collected. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

66. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer T echnology appraisal guidance Published: 15 January 2020 www.nice.org.uk/guidance/ta619 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

67. Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)

Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) Atezolizumab with carboplatin and nab- paclitaxel for untreated advanced non-squamous non- small-cell lung cancer (terminated appraisal) T echnology appraisal guidance Published: 15 January 2020 www.nice.org.uk/guidance/ta618 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Contents (...) Contents Advice 3 Information 3 Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small- cell lung cancer (terminated appraisal) (TA618) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 3Advice Advice NICE is unable to make a recommendation about the use in the NHS of atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

68. Routine Human Papilloma Virus (HPV) Testing in Squamous Cell Head and Neck Cancer

Routine Human Papilloma Virus (HPV) Testing in Squamous Cell Head and Neck Cancer Evidence-Based Series 5-9 Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Routine HPV Testing in Head and Neck Squamous Cell Carcinoma The Expert Panel on HPV Testing in Head and Neck Squamous Cell Carcinoma January 13, 2020 Evidence-Based Series 5-9 was reviewed in 2019 and ENDORSED by the Expert Panel on HPV Testing in Head and Neck Squamous Cell Carcinoma (...) . See Section 4: Document Assessment and Review for details. EBS 5-9 is comprised of 4 sections. You can access the summary and full report here: https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/581 Section 1: Guideline Recommendations (ENDORSED) Section 2: Evidentiary Base Section 3: EBS Development Methods and External Review Process Section 4: Document Assessment and Review For information about the PEBC and the most current version of all reports, please visit the CCO

2020 Cancer Care Ontario

69. Abiraterone acetate (Zytiga) - for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer

Abiraterone acetate (Zytiga) - for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer 1 Published 13 January 2020 1 SMC2215 abiraterone acetate 500mg film-coated tablets (Zytiga®) Janssen-Cilag Ltd 6 December 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following (...) a full submission assessed under the orphan medicine process abiraterone acetate (Zytiga ® ) is accepted for use within NHSScotland. Indication under review: abiraterone acetate with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer in adult men in combination with androgen deprivation therapy. Abiraterone acetate in combination with prednisone and androgen deprivation therapy demonstrated superiority over androgen deprivation

2020 Scottish Medicines Consortium

70. OWise mobile app and website for supporting women with breast cancer - Innovative Medical Technology Overview

OWise mobile app and website for supporting women with breast cancer - Innovative Medical Technology Overview IMTO | 1 IMTO 02-20 January 2020 OWise mobile app and website for supporting women with breast cancer Innovative Medical Technology Overview Key points ? OWise Breast Cancer is an app and website that offer a suite of tailored information and tools to support women with breast cancer. ? Included in the OWise app is information on disease pathology and care pathways, tailored questions (...) to prompt discussion with healthcare practitioners, an audio- recording function for use in consultations, a symptom tracker and an appointment diary. The ability to share patient symptom data in real-time with the NHSScotland TrakCare® patient record system is being evaluated in NHS Lothian. ? The OWise app is designed for use throughout the patient journey, in conjunction with standard treatments for breast cancer, as a replacement for paper-based support tools. ? There are currently no published

2020 SHTG Advice Statements

71. Role of intermittent pneumatic compression in the treatment of breast cancer-related lymphoedema: a randomized controlled trial

Role of intermittent pneumatic compression in the treatment of breast cancer-related lymphoedema: a randomized controlled trial Role of Intermittent Pneumatic Compression in the Treatment of Breast Cancer-Related Lymphoedema: A Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features (...) a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Clin Rehabil Actions , 269215519888792 2019 Dec 4 [Online ahead of print] Role of Intermittent Pneumatic Compression in the Treatment of Breast Cancer-Related Lymphoedema: A Randomized Controlled Trial , , , , , , Affiliations Expand Affiliations 1 Department of Physical Medicine

2020 EvidenceUpdates

72. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline EndoscopicmanagementofLynchsyndromeandof familialriskof colorectalcancer:EuropeanSocietyofGastrointestinalEndoscopy (ESGE) Guideline Authors MoniqueE. vanLeerdam 1,2 ,VictorineH.Roos 3 ,JeaninE.vanHooft 3 ,FrancescBalaguer 4,5 ,EvelienDekker 3 ,MichalF. Kaminski 6,7,8 ,AndrewLatchford 9,10 ,HelmutNeumann 11 ,LuigiRicciardiello 12 ,MariaRupinska 6,7 (...) ,Jean-Christophe Saurin 13 ,PieterJ.Tanis 14 ,AnjaWagner 15 ,RodrigoJover 16 ,MariaPellisé 4,5 Institutions ?1 Department of Gastroenterology and Hepatology, Netherlands Cancer Institute, Amsterdam, The Netherlands ?2 Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands, Foundation for the Detection of Hereditary Tumours, Leiden, The Netherlands ?3 Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, University

2020 European Society of Gastrointestinal Endoscopy

73. eUpdate – Bladder Cancer Treatment Recommendations

eUpdate – Bladder Cancer Treatment Recommendations Bladder Cancer Treatment Recommendations | ESMO Welcome to the EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY , the leading European professional organisation for medical oncology. Search Careers at ESMO ESMO Oncology Journals Our journals offer ESMO members and the oncology community a globally visible platform to publish scientific studies, and a highly credible source of educational updates.​ Connect with ESMO Discover ESMO's new social media (...) , including the latest CPG publications, updated recommendations, algorithms, pocket guidelines and MCBS grading ESMO Guidelines Slide Sets Quick and easy access to the essential content of the guidelines – PowerPoint slides and PDFs including algorithms, figures and tables – free to download Breast Cancer Early Breast Cancer • 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC4) • Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer

2020 European Society for Medical Oncology

74. Shared follow-up care for early breast cancer: summary of evidence

Shared follow-up care for early breast cancer: summary of evidence canceraustralia.gov.au 1 The need for new models of follow-up care for breast cancer Shared follow-up care for early breast cancer is an innovative model of care that supports the provision of holistic follow-up and survivorship care following active treatment. With high incidence and increasing survivorship following a diagnosis of breast cancer, progressively more people will require follow-up care, placing an increased demand (...) on Australia’s health system and resources. Shared care leverages the skills and expertise of the specialist and primary care workforce to support the delivery of high quality, safe and sustainable follow-up and survivorship care. Breast cancer will affect 1 in 7 people in Australia in their lifetime. It is estimated that 19,535 people will be diagnosed with the disease in Australia in 2019 (19,371 women and 164 men). 1 Australians experience some of the highest cancer survival rates in the world. 2,3 Breast

2020 Cancer Australia

75. Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer (Epub draft)

Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer (Epub draft) CUAJ – CUA Guideline So et al Guideline: mCNPC & mCSPC Canadian Urological Association-Canadian Urologic Oncology Group guideline on Metastatic castration-naive and castration-sensitive prostate cancer Alan So 1 ; Kim Chi 2 ; Brita Danielson 3 ; Neil Fleshner 4 ; Anil Kapoor 5 ; Tamim Niazi 6 ; Frederic Pouliot 7 ; Ricardo Rendon 8 (...) , Division of Radiation Oncology, McGill University, Montreal QC, Canada; 7 Division of Urology, Department of Surgery, Université Laval, Quebec, QC, Canada; 8 Department of Urology, Dalhousie University, Halifax, NS, Canada; 9 Division of Hematology and Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada; 10 Department of Radiation Oncology, CHUQ, Université Laval, Quebec City, QC, Canada; 11 Department of Surgery, Université de

2020 Canadian Urological Association

76. Principles of shared follow-up care for early breast cancer

Principles of shared follow-up care for early breast cancer canceraustralia.gov.au Principles of shared follow-up care for early breast cancer SHARED FOLLOW-UP AND SURVIVORSHIP CARE FOR EARLY BREAST CANCER Cancer Australia’s seven Principles of shared follow-up care for early breast cancer are designed to underpin the delivery of shared follow-up and survivorship care for early breast cancer by health professionals and health services. Person-centred care The individual and their whole person (...) the provision of education, resources, information for people affected by cancer and pathways for access to specialist advice. Care is delivered according to best practice Provision of care is in accordance with nationally agreed standards and is outcome-focused. Individual follow-up care includes identified pathways for timely access to specialist providers as required. Support for the specialist treatment team The role of specialist care providers in the delivery of safe and effective follow-up care

2020 Cancer Australia

77. The safety of uterine manipulators in minimally hysterectomy for endometrial cancer: a systematic review and meta-analysis

The safety of uterine manipulators in minimally hysterectomy for endometrial cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

78. The experiences of cancer patients participating in phase one clinical trials: a systematic review and synthesis of the qualitative evidence

The experiences of cancer patients participating in phase one clinical trials: a systematic review and synthesis of the qualitative evidence Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2020 PROSPERO

79. The effects of omega-3 polyunsaturated fatty acids on postoperative complications and inflammatory responses of esophageal cancer: a meta-analysis

The effects of omega-3 polyunsaturated fatty acids on postoperative complications and inflammatory responses of esophageal cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

80. The effects of mindfulness-based interventions on symptoms of depression, anxiety, and cancer-related fatigue in oncology patients: a systematic review and meta-analysis

The effects of mindfulness-based interventions on symptoms of depression, anxiety, and cancer-related fatigue in oncology patients: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2020 PROSPERO